Ptc Therapeutics (PTCT) Total Liabilities (2012 - 2026)

Ptc Therapeutics' Total Liabilities history runs 15 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 7.34% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 7.34% increase from a year earlier, with the FY2025 full-year figure at $3.1 billion, up 10.74% from the prior year.
• Total Liabilities retreated to $3.0 billion in Q1 2026 per PTCT's latest filing, from $3.1 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $3.1 billion in Q4 2025 and bottomed at $1.8 billion in Q3 2022.
• The 5-year median for Total Liabilities is $2.7 billion (2023), against an average of $2.5 billion.
• Across the five-year window, Total Liabilities dropped 5.21% in 2022 and jumped 51.07% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $2.1 billion in 2022, then soared by 32.23% to $2.7 billion in 2023, then gained by 3.27% to $2.8 billion in 2024, then advanced by 10.74% to $3.1 billion in 2025, then retreated by 1.76% to $3.0 billion in 2026.
• Per Business Quant, the three latest PTCT Total Liabilities figures stand at $3.0 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.8 billion (Q3 2025).